

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Malaria	Unknown	<p>A study in mice and in cell culture identified a ferroquine derivative, trioxaferroquine, which could help treat malaria. In two strains of chloroquine-resistant <i>Plasmodium falciparum</i>, trioxaferroquine had antimalarial activity with IC<sub>50</sub> values of 20 and 17 nM. In mice infected with <i>P. vinckei petteri</i>, trioxaferroquine reduced parasite load and increased survival compared with no treatment. Next steps could include developing trioxaferroquines with improved antiparasitic activity.</p> <p>The generic chloroquine is approved to treat malaria.</p> <p>sanofi-aventis Group's chloroquine derivative, ferroquine (SSR97193), is in Phase II testing to treat malaria.</p> <p><b>SciBX 3(21); doi:10.1038/scibx.2010.650</b> Published online May 27, 2010</p>	Patent and licensing status unavailable	<p>Bellot, F. <i>et al.</i> <i>J. Med. Chem.</i>; published online May 5, 2010; doi:10.1021/jm100117e</p> <p><b>Contact:</b> Anne Robert, Centre National de la Recherche Scientifique (CNRS), Toulouse, France e-mail: <a href="mailto:anne.robert@lcc-toulouse.fr">anne.robert@lcc-toulouse.fr</a></p>